737 research outputs found

    Veterans\u27 Reemployment Rights Expanded (Palmarozzo v. Coca-Cola Bottling Co.)

    Get PDF

    Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study

    Get PDF
    Breast cancer; Pharmacogenomics; Tumour biomarkersCáncer de mama; Farmacogenómica; Biomarcadores tumoralesCàncer de mama; Farmacogenòmica; Biomarcadors tumoralsThese analyses explore the impact of homologous recombination repair gene mutations, including BRCA1/2 mutations and homologous recombination deficiency (HRD), on the efficacy of the poly(ADP-ribose) polymerase (PARP) inhibitor talazoparib in the open-label, two-cohort, Phase 2 ABRAZO trial in germline BRCA1/2-mutation carriers. In the evaluable intent-to-treat population (N = 60), 58 (97%) patients harbor ≥1 BRCA1/2 mutation(s) in tumor sequencing, with 95% (53/56) concordance between germline and tumor mutations, and 85% (40/47) of evaluable patients have BRCA locus loss of heterozygosity indicating HRD. The most prevalent non-BRCA tumor mutations are TP53 in patients with BRCA1 mutations and PIK3CA in patients with BRCA2 mutations. BRCA1- or BRCA2-mutated tumors show comparable clinical benefit within cohorts. While low patient numbers preclude correlations between HRD and efficacy, germline BRCA1/2 mutation detection from tumor-only sequencing shows high sensitivity and non-BRCA genetic/genomic events do not appear to influence talazoparib sensitivity in the ABRAZO trial.In Manchester, this trial was undertaken in/supported by the NIHR Manchester Clinical Research Facility at The Christie Hospital NHS Foundation Trust. The ABRAZO study was sponsored by Medivation, which was acquired by Pfizer in September 2016 (grant number not applicable). The authors wish to thank Masaki Mihaila and the Pfizer clinical programming team for the ABRAZO correlative analyses. Medical writing support was provided by Dominic James, PhD, and Hannah Logan, PhD, of CMC AFFINITY, a division of IPG Health Medical Communications, and was funded by Pfizer

    Alterations in amino acid status in cats with feline dysautonomia

    Get PDF
    Feline dysautonomia (FD) is a multiple system neuropathy of unknown aetiology. An apparently identical disease occurs in horses (equine grass sickness, EGS), dogs, rabbits, hares, sheep, alpacas and llamas. Horses with acute EGS have a marked reduction in plasma concentrations of the sulphur amino acids (SAA) cyst(e)ine and methionine, which may reflect exposure to a neurotoxic xenobiotic. The aim of this study was to determine whether FD cats have alterations in amino acid profiles similar to those of EGS horses. Amino acids were quantified in plasma/serum from 14 FD cats, 5 healthy in-contact cats which shared housing and diet with the FD cats, and 6 healthy control cats which were housed separately from FD cats and which received a different diet. The adequacy of amino acids in the cats’ diet was assessed by determining the amino acid content of tinned and dry pelleted foods collected immediately after occurrences of FD. Compared with controls, FD cats had increased concentrations of many essential amino acids, with the exception of methionine which was significantly reduced, and reductions in most non-essential amino acids. In-contact cats also had inadequate methionine status. Artefactual loss of cysteine during analysis precluded assessment of the cyst(e)ine status. Food analysis indicated that the low methionine status was unlikely to be attributable to dietary inadequacy of methionine or cystine. Multi-mycotoxin screening identified low concentrations of several mycotoxins in dry food from all 3 premises. While this indicates fungal contamination of the food, none of these mycotoxins appears to induce the specific clinico-pathologic features which characterise FD and equivalent multiple system neuropathies in other species. Instead, we hypothesise that ingestion of another, as yet unidentified, dietary neurotoxic mycotoxin or xenobiotic, may cause both the characteristic disease pathology and the plasma SAA depletion

    High Latitude Radio Emission in a Sample of Edge-On Spiral Galaxies

    Get PDF
    We have mapped 16 edge-on galaxies at 20 cm using the VLA. For 5 galaxies, we could form spectral index, energy and magnetic field maps. We find that all but one galaxy show evidence for non-thermal high latitude radio continuum emission, suggesting that cosmic ray halos are common in star forming galaxies. The high latitude emission is seen over a variety of spatial scales and in discrete and/or smooth features. In general, the discrete features emanate from the disk, but estimates of CR diffusion lengths suggest that diffusion alone is insufficient to transport the particles to the high latitudes seen (> 15 kpc in one case). Thus CRs likely diffuse through low density regions and/or are assisted by other mechanisms (e.g. winds). We searched for correlations between the prevalence of high latitude radio emission and a number of other properties, including the global SFR, supernova input rate per unit star forming, and do not find clear correlations with any of these properties.Comment: 40 pages of text, 3 figures, 6 tables, and an appendix of 21 jpeg figures (which is a radio continuum catalogue of 17 galaxies). to appear in A. J. (around January 1999

    Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV Type 1-infected subjects over 48 weeks

    Get PDF
    We assessed metabolic changes for darunavir/ritonavir (DRV/r) once daily (qd) versus atazanavir/ritonavir (ATV/r) qd with fixed-dose tenofovir/emtricitabine. This was a phase 4, multicenter, open-label, randomized exploratory study. Treatment-naive, HIV-1-infected adults received DRV/r 800/100 mg qd or ATV/r 300/100 mg qd, both with emtricitabine/tenofovir 200/300 mg qd. Primary end point: change in triglyceride levels from baseline to week 12. Secondary end points: week 12 and week 48 changes in lipid parameters, insulin sensitivity, inflammatory/coagulation/bacterial translocation biomarkers, viral load, CD4(+) cell count, and week 48 changes in adipose tissue distribution and subjects' perceptions of body changes. In the DRV/r arm, 32/34 and 29/34 subjects completed weeks 12 and 48, respectively; in the ATV/r arm, 30/31 and 25/31 subjects completed weeks 12 and 48, respectively. Small changes in lipid parameters from baseline to weeks 12 and 48 were observed in both arms. Differences were noted between arms in mean changes in total cholesterol (DRV/r, 20.3 mg/dl; ATV/r, 4.6 mg/dl) and apolipoprotein A1 (DRV/r, 10.7 mg/dl; ATV/r, –0.7 mg/dl) at week 12. At week 48, no clinically relevant differences between arms were noted for changes in any lipid parameter, fasting glucose, or insulin sensitivity. Biomarkers generally decreased and efficacy parameters improved in both arms over 48 weeks. Changes in adipose tissue were small and comparable between arms. Subjects' perceptions of body changes generally improved in both study arms. This first pilot comparison in HIV-1-infected subjects suggests that DRV/r has a metabolic profile similar to ATV/r over 48 weeks of treatment. Further randomized studies are warranted

    Functional MRI Evaluation of Multiple Neural Networks Underlying Auditory Verbal Hallucinations in Schizophrenia Spectrum Disorders.

    Get PDF
    Functional MRI studies have identified a distributed set of brain activations to be asso­ ciated with auditory verbal hallucinations (AVH). However, very little is known about how activated brain regions may be linked together into AVH-generating networks. Fifteen volunteers with schizophrenia or schizoaffective disorder pressed buttons to indicate onset and offset of AVH during fMRI scanning. When a general linear model was used to compare blood oxygenation level dependence signals during periods in which subjects indicated that they were versus were not experiencing AVH ( AVH-on versus AVH-off ), it revealed AVH-related activity in bilateral inferior frontal and superior temporal regions; the right middle temporal gyrus; and the left insula, supramarginal gyrus, inferior parietal lobule, and extranuclear white matter. In an effort to identify AVH-related networks, the raw data were also processed using independent component analyses (ICAs). Four ICA components were spatially consistent with an a priori network framework based upon published meta-analyses of imaging correlates of AVH. Of these four components, only a network involving bilateral auditory cortices and posterior receptive language areas was significantly and positively correlated to the pattern of AVH-on versus AVH-off. The ICA also identified two additional networks (occipital-temporal and medial prefrontal), not fully matching the meta-analysis framework, but nevertheless containing nodes reported as active in some studies of AVH. Both networks showed significant AVH-related profiles, but both were most active during AVH-off periods. Overall, the data suggest that AVH generation requires specific and selective activation of auditory cortical and posterior language regions, perhaps coupled to a release of indirect influence by occipital and medial frontal structures

    An inventory of supranational antimicrobial resistance surveillance networks involving low- and middle-income countries since 2000.

    Get PDF
    Low- and middle-income countries (LMICs) shoulder the bulk of the global burden of infectious diseases and drug resistance. We searched for supranational networks performing antimicrobial resistance (AMR) surveillance in LMICs and assessed their organization, methodology, impacts and challenges. Since 2000, 72 supranational networks for AMR surveillance in bacteria, fungi, HIV, TB and malaria have been created that have involved LMICs, of which 34 are ongoing. The median (range) duration of the networks was 6 years (1-70) and the number of LMICs included was 8 (1-67). Networks were categorized as WHO/governmental (n = 26), academic (n = 24) or pharma initiated (n = 22). Funding sources varied, with 30 networks receiving public or WHO funding, 25 corporate, 13 trust or foundation, and 4 funded from more than one source. The leading global programmes for drug resistance surveillance in TB, malaria and HIV gather data in LMICs through periodic active surveillance efforts or combined active and passive approaches. The biggest challenges faced by these networks has been achieving high coverage across LMICs and complying with the recommended frequency of reporting. Obtaining high quality, representative surveillance data in LMICs is challenging. Antibiotic resistance surveillance requires a level of laboratory infrastructure and training that is not widely available in LMICs. The nascent Global Antimicrobial Resistance Surveillance System (GLASS) aims to build up passive surveillance in all member states. Past experience suggests complementary active approaches may be needed in many LMICs if representative, clinically relevant, meaningful data are to be obtained. Maintaining an up-to-date registry of networks would promote a more coordinated approach to surveillance

    The Ursinus Weekly, April 25, 1974

    Get PDF
    Jeane Dixon arrives at Ursinus College • Bruce Springsteen and band a big hit in Helfferich at first major rock music concert at Ursinus • Editorial staff named for Ursinus Weekly • Two more forums planned for April • IRC participates in Model UN • Committee meets on women’s hours • Editorial: Does anybody really care? • Jeane Dixon: Before it all happened • Union’s learn-ums: Mini-courses galore • Volunteers help special students • C. Vaughn Fitzgerald meets the challenge of London culture and energy crisis • Gutman speaks to Ec club • Freshman Mark Sellers new college chess champ • Travelin’ 7 benefits Pierce scholarship fund • The Zodiac: The water signs: Cancer, Scorpio, Pisces • Songfest slated for April 30 • Women’s Lacrosse hosts “all college” tri-outs • U.C. runs awayhttps://digitalcommons.ursinus.edu/weekly/1014/thumbnail.jp
    • …
    corecore